SCHEMBL2777586

SCHEMBL2777586

CCOC(=O)c1nc(C#N)c2c(-c3ccc(OC)cc3)noc2c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.47
PDCD4 Q53EL6 1/20 0.47
HPGD P15428 4/20 0.46
HTT P42858 3/20 0.43
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
RECQL P46063 1/20 0.40
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
THRB P10828 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GLA P06280 1/20 0.38
UBE2N P61088 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773625 0.89 SLC26A6 (0.44) HPGDGAAALDH1A1KDM4EKMT2A
SCHEMBL2777550 0.87 TARBP2 (0.51) TARBP2PDCD4HTTPOLBGAA
SCHEMBL3660963 0.87 PTGS2 (0.41) HPGDALDH1A1KMT2AMAPTRECQL
SCHEMBL2779518 0.86 TARBP2 (0.50) TARBP2PDCD4HTTPOLBGAA
SCHEMBL2780504 0.84 TARBP2 (0.48) TARBP2PDCD4HTTPOLBGAA
SCHEMBL2773774 0.83 TARBP2 (0.51) TARBP2PDCD4HTTPOLBGAA
SCHEMBL2776313 0.82 EGLN1 (0.46) HPGDALDH1A1KDM4ETHRBPTGS1
SCHEMBL3714404 0.82 ADORA1 (0.39) HPGDGAAALDH1A1KDM4EMAPT
SCHEMBL2776836 0.81 KDM4E (0.46) TARBP2HPGDHTTALDH1A1KDM4E
SCHEMBL2776472 0.81 TARBP2 (0.49) TARBP2PDCD4HTTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 TARBP2 4814/4885PDCD4 1962/4885HPGD 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.